A total of 42 consecutive patients with PD who underwent STN-DBS were enrolled in this study.
Sunovion announced that the FDA has accepted the NDA for apomorphine sublingual film to treat motor fluctuations seen in patients with Parkinson's.
The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive StrategiesJune 12, 2018
More than half of patients diagnosed with Parkinson disease experience freezing of gait.
Surgical interventions for Parkinson disease are experiencing a swell in innovation, thanks in part to the entry of two additional medical device companies into a field previously dominated by one company.
There is a significantly increased risk of Parkinson disease in patients with inflammatory bowel disease.
Risk factors for all study participants were calculated on the basis of the following factors known to be previously linked to PD risk: total caffeine intake, smoking, physical activity, and family history of PD.
Patients with IBD who were exposed to anti-TNF therapy had a significant decrease in incidence of PD.
Non-invasive neuromodulation therapy using a custom stimulation pattern provides symptomatic relief from hand tremor in essential tremor.
Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.
Previous research has suggested a genetic and functional link between IBD and PD, however evidence regarding this association has been limited.
Researchers sought to assess outcomes in hospitalized patients with comorbid Parkinson disease and major depressive disorder following administration of deep brain stimulation.
In this article, we explore research findings to provide a deeper understanding of the factors associated with increased risk for impulse control disorders in Parkinson disease. Deputy Director of the Parkinson's UK charity, Professor David Dexter, also provides insights on the mechanisms of impulse control disorders and the implications of new findings on the management of Parkinson disease.
Researchers say that tears may be an inexpensive, reliable, and noninvasive biological marker of Parkinson's disease.
Demoralization is common in patients with Parkinson disease and is associated with motor dysfunction.
Although deep brain stimulation, similar to all Parkinson disease therapies, cannot cure, modify, or slow progression of the disease, some recent research suggests that the symptom alleviation and quality-of-life improvement it provides might lead to mild improvements in longevity.
The office-based, eight-item Montreal Parkinson Risk of Dementia Scale is a valid predictor of development of dementia.
Sunovion announced the submission of its New Drug Application for apomorphine sublingual film for OFF episodes linked with PD.
Idiopathic Parkinson disease is independently associated with an increased risk for overactive bladder.
Investigators sought to determine whether brain pattern metabolic alterations in PD and FDG-PET SPM could predict dementia risk.
The use of subthalamic stimulation may be beneficial in managing psychobehavioral manifestations of Parkinson disease.
It may be best to deal with the PD subtype characterized by gait difficulty differently from the akinetic-rigid subtype.
The FDA has approved Osmolex ER for the treatment of Parkinson disease.
A significant negative correlation was found between the individual Unified Parkinson's Disease Rating Scale motor improvement and the Euclidean distance from the stimulation center to the deep brain stimulation "hotspot" when using the medial subthalamic nucleus border as an anatomical reference.
By 10 weeks, participants in the treatment group reported significant improvements in quality of life.
Apomorphine sublingual film showed superior efficacy for on-demand treatment of OFF episodes in patients with Parkinson's.
In patients with Parkinson disease, cable-driven robot training is linked with improved response to perturbations and increased gait stability.
Deep brain stimulation does not show significant improvements in cognitive outcomes for patients with Parkinson disease dementia.
In Parkinson's patients who are cognitively normal or have mild cognitive impairment, patterns of cortical β-amyloid and tau are not different.
Investigators determined the association between motor-cognitive dual task gait performance and cognitive impairment.
Several studies have uncovered sex-dependent variations in the symptomatic manifestations of Parkinson disease, as well as in the response to dopamine therapies.
Neurology Advisor Articles
- Weighing the Risks of Deep Brain Stimulation
- Dietary Supplements in MS: Exercising Caution With OTC Remedies
- Cladribine May Be Beneficial for Managing Progressive Multiple Sclerosis
- Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis
- Transcranial Doppler Ultrasound Timing Critical for Beneficial Outcomes Following Stroke Thrombolysis
- Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds
- Patients' Preferences for Physician Attire Linked to Perception of Care
- Weighing the Risks of Deep Brain Stimulation
- Grey Matter Atrophy Sequence in Multiple Sclerosis Phenotypes
- Higher Vitamin D Levels Associated With Fewer Lesions in Multiple Sclerosis
- No Significant Clinical Differences Between Cluster Headaches With and Without Aura
- Tetrabenazine Not Associated With Increased Depression or Suicide
- The Role of Neurogenic Inflammation in Fibromyalgia Pathophysiology
- IT Solutions for Easier EHRs Save Physicians Time, Burnout
- FDA Drops Zika Testing for Blood Donors